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Abstract
Due to the heterogeneity of existing European sources of observational healthcare data,
data source-tailored choices are needed to execute multi-data source, multi-national
epidemiological studies. This makes transparent documentation paramount. In this proof-
of-concept study, a novel standard data derivation procedure was tested in a set of hetero-
geneous data sources. Identification of subjects with type 2 diabetes (T2DM) was the test
case. We included three primary care data sources (PCDs), three record linkage of adminis-
trative and/or registry data sources (RLDs), one hospital and one biobank. Overall, data
from 12 million subjects from six European countries were extracted. Based on a shared
event definition, sixteeen standard algorithms (components) useful to identify T2DM cases
were generated through a top-down/bottom-up iterative approach. Each component was
based on one single data domain among diagnoses, drugs, diagnostic test utilization and
laboratory results. Diagnoses-based components were subclassified considering the
healthcare setting (primary, secondary, inpatient care). The Unified Medical Language Sys-
tem was used for semantic harmonization within data domains. Individual components
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were extracted and proportion of population identified was compared across data sources.
Drug-based components performed similarly in RLDs and PCDs, unlike diagnoses-based
components. Using components as building blocks, logical combinations with AND, OR,
AND NOT were tested and local experts recommended their preferred data source-tailored
combination. The population identified per data sources by resulting algorithms varied from
3.5% to 15.7%, however, age-specific results were fairly comparable. The impact of individ-
ual components was assessed: diagnoses-based components identified the majority of
cases in PCDs (93–100%), while drug-based components were the main contributors in
RLDs (81–100%). The proposed data derivation procedure allowed the generation of data
source-tailored case-finding algorithms in a standardized fashion, facilitated transparent
documentation of the process and benchmarking of data sources, and provided bases for
interpretation of possible inter-data source inconsistency of findings in future studies.
Introduction
In recent years, an increasing number of projects have been focusing on re-using existing elec-
tronic health records (EHR) for clinical research.[1] In particular, huge efforts have been made
to combine health data from isolated environments and perform valid multi-data source obser-
vational studies.[2, 3]
In this context, the European Medical Information Framework (EMIF) project was
launched with the main objective of building an infrastructure for the efficient re-use of exist-
ing European health care data for epidemiological research (http://www.emif.eu/). Within the
project, a federation of heterogeneous sources of real world data (e.g. administrative, hospital
or primary care databases, disease registries, biobanks), currently collecting health information
on around 52 million European citizens, collaborate in the EMIF-Platform whose focus is the
consistent exploitation of currently available patient-level data to support novel research. One
of the main challenges for the EMIF-Platform is to deal with the heterogeneous characteristics
of the participating data sources and facilitate the execution of high quality multi-national,
multi-data source observational studies based on populations with otherwise unconceivable
sample sizes and follow-up time span.
In general, different strategies can be adopted to identify a population of interest from a sin-
gle source of EHR.[4, 5] The choice of a particular case-finding algorithm is generally driven by
both the specific research question and the data source peculiarities.[6] The chosen algorithm,
however, can significantly affect the characteristics of the cases identified [4, 5] and, for this
reason, should be carefully taken into account when discussing study results.
In multi-data source studies, tailored choices may be necessary [6–8], and the diversity of
local case-identification algorithms may increase along with the heterogeneity of the data
sources involved [6, 9, 10]. A transparent process of documentation and evaluation of local
case-finding algorithms becomes paramount for the correct interpretation of study results as
well as for the discussion of possible inter-data source inconsistency of study findings [10–12].
It must be noted that data sources available to study European populations are much more het-
erogeneous than data sources from a single country, such as the United States [10]. Therefore,
in order to address this issue, the EMIF-Platform designed a novel standard procedure for data
derivation which leverages the experience gained from previous European multi-national,
multi-data source studies [2, 3, 9, 13]. In this proof-of-concept study, the identification of type
2 diabetes mellitus (T2DM), a common chronic condition with important implications for
future health[14], was used as a test case.
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Materials and Methods
Data sources
Eight European data sources collecting health care information on around 20 million subjects
from six different countries participated to this study (Table 1). Three were primary care data
sources (PCDs), three were record linkage systems of different registries (RLDs), one was a
hospital data source (HD) and one was a biobank (BD). In specific, the three primary care data
sources were the Health Search IMS Health LPD database (HSD, Italy),[9, 15] the Integrated
Primary Care Information database (IPCI, The Netherlands)[16] and The Health Improve-
ment Network database (THIN, UK), in which the general practitioners (GPs) function as data
keeper of all patient’s medical information.[17] The three record linkage data sources were the
Aarhus University Hospital (AUH, Aarhus, Denmark),[18, 19] PHARMO (PHARMO, The
Netherlands)[20] and the Regional Health Authority of Tuscany (ARS, Italy),[9, 15] which col-
lect data from different sources (e.g. hospital discharge records, death registries, drug dispens-
ing and procedures). The HD was the Information System of Parc de Salut Mar Barcelona
(IMASIS, Spain) that records information from routine healthcare activities of Hospital del
Mar of Barcelona.[21, 22] The BD was the Estonian Genome Center of University of Tartu
Table 1. Data sources’ characteristics*.
Data source (Original
organizationacronym)
Type of
data
source
Catchment
area
Cumulative
number of
participants in
the database
Average
follow-up
time
Diagnoses
• setting,
• coding
system
Medication
(coding
system)
Diagnostic
procedures/
tests (coding
system)
Laboratory
results (coding
system for
measurments)
RLD-I (ARS) Record
linkage
system
Tuscany (Italy) 5 millions 9 years • Inpatient
• ICD9CM
ATC ICD9CM or
local
terminology
-
RLD-DK (AUH) Record
linkage
system
The northern
and central
region of
Jutland.
(Denmark)
2.3 millions 13 years • Inpatient,
secondary care
• ICD10
ATC NOMESCO -
RLD-N (PHARMO) Record
linkage
system
Netherlands
(Certain
regions, mainly
South East and
North-West)
10 millions 10 years • Inpatient
• ICD9CM
ATC Local
terminology
Local
terminology
PCD-I (HSD) Primary
care
Italy 2.3 millions 10 years • Primary care
• ICD9CM
ATC Local
terminology
Local
terminology
PCD-UK (THIN) Primary
care
United
Kingdom
12 millions 9 years • Primary care,
READ
ATC Local
terminology
Local
terminology
PCD-N (IPCI) Primary
care
Netherlands 2.8 millions 3 years • Primary care
• ICPC/free text
ATC Local
terminology
Local
terminology
HD (IMASIS) Hospital Barcelona
(three city
districts)
1.5 millions 5 years • Admissions,
outpatients,
major
ambulatory
surgery and
emergency
room
• ICD9CM
Local
terminology &
the Spanish
Medicines
Agency codes
ICD9CM Local
terminology
BD (EGCUT) Biobank Estonia 52000 Not
applicable
• Primary care/
Self reported
• ICD10
ATC Local
terminology
Local
terminology
*Information reported in the table is updated at January 2013.
doi:10.1371/journal.pone.0160648.t001
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(EGCUT, Estonia) in which information from interviews of voluntary donors of biological
samples is collected through standard questionnaires.[23] EGCUT is the only cross-sectional
data source included in this study. In all data sources except the Spanish HD, IMASIS, informa-
tion on a representative sample of the population living in the corresponding geographic area
are collected. In the Italian PCD and in the Estonian BD only adult population is represented
(>14 and>18 years of age, respectively). The information in the corresponding databases is
recorded using different coding systems. Diagnoses are coded according to the International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) or ICD-10 (10th
version), the International Classification of Primary Care (ICPC), READ or are as free text.
Prescriptions/dispensings are coded according to the Anatomical Therapeutic Chemical classi-
fication (ATC) or BNF/Multilex. The majority of the data sources collect records concerning
the utilization of diagnostic procedures and laboratory results. The coding of these data
domains are based on local service terminologies.
Study population and design
In each participating data source the study population corresponded to all active subjects on
January the 1st 2012 (reference date) that at the same date had16 years of age. Due to sample
size issues, exception was made for EGCUT in which January the 1st 2009 was considered as
the reference date.
A descriptive, cross-sectional, retrospective multi-database study was performed. Patients
with T2DM were identified within the populations selected from the participating data sources
by using different case-finding algorithms.
Event definition
T2DM is a chronic clinical condition characterized by hyperglycemia due to insulin resistance
and a progressive deficiency in insulin production[14]. It represents the most common form of
diabetes, comprising about 90% of all cases of diabetes worldwide[24]. Diagnosis and follow-
up of T2DM is based on laboratory tests for blood glucose measurements and treatment
includes life style interventions (i.e. diet and physical exercise) and use of medications[14].
As the first step of the data derivation procedure, a shared clinical definition of T2DM was
adopted (Fig 1) and defined according to the European Society of Cardiology and European
Association for the Study of Diabetes (ESC/EASD) guideline[14].
Generation of a list of component algorithms
To identify subjects with T2DM in a healthcare data source, information from one or more
data domains may be available. Diagnoses and/or records collecting information on routine
patients’ clinical care and follow-up, such as drug prescriptions, utilization of diagnostic tests
and laboratory results, can be used,[4, 25, 26] so that combining data from one or more of
these domains, different case-finding strategies, with different sensitivity and positive predic-
tive value (PPV), can be obtained.[4]
As the second step of the data derivation procedure a unique list of standard algorithms use-
ful to identify cases of T2DM in the selected data sources was generated. Such standard algo-
rithms, referred to as “component algorithms”, were defined as rules to identify subjects with a
defined pattern of records selected from a single data domain. For the identification of T2DM,
a total of four data domains were concerned: diagnoses (DIAG), drug prescription/dispensing
(DRUG), utilization of a diagnostic test (TEST) or laboratory results (LABVAL). Component
algorithm could be intended as inclusion, exclusion or refinement criteria. Two sources of
knowledge were leveraged and integrated for the design of the component algorithms: a central
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expert-based definition of T2DM (top-down engineering) and the expertise provided by local
data source experts (bottom-up learning).[8] The top-down engineering was embedded in the
previously mentioned clinical definition (see previous subsection) and in an operational defini-
tion. The latter was intended as a description of typical diagnostic and therapeutic patterns that
patients with T2DM are expected to follow. Both the clinical and operational definition were
created by researchers with clinical expertise and agreed with both the local data source experts
and the central study leader. The bottom-up learning, instead, was embedded in a question-
naire where local experts were asked to describe the algorithms they would have used to iden-
tify T2DM cases in their own data source, possibly mentioning relevant validation studies. All
the information gathered were then used by the central study leader to create a unique list of
inclusion, exclusion and refinement criteria corresponding to those mentioned at least once in
one of the documents generated. The list was created on the grounds of the central study lead-
ers' judgement and revised by the clinical and local experts. Each criterion was then translated
into a standard component algorithm, as follow. As already described in greater details in a
previous published paper,[3] the Unified Medical Language System (UMLS) was used to build
a shared semantic foundation across the different coding systems: medical concepts pertinent
to the clinical and operational definition of T2DM were identified and projected to local termi-
nologies. The final list of local codes, strings and free text keywords was obtained through an
iterative process involving local experts’ feedback. Each component algorithm was fully
described by two additional rules: the first was the pattern of records that triggers identification
Fig 1. The standard procedure for data derivation.
doi:10.1371/journal.pone.0160648.g001
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of the event (for instance: at least two records in the same calendar year), and the second con-
cerned the criteria to identify the case’s index date (e.g. date of the first record).
Data extraction and analysis: “the component algorithm strategy”
A distributed network approach was adopted in EMIF to allow partners for maintaining con-
trol of their data and to benefit from local data source experts consultation on the appropriate
use of data and interpretation of results.[2, 3] Local experts were asked to select and extract all
component algorithms considered useful to identify T2DM cases in their data source. All per-
son-time available up to the reference date was considered for algorithm application. Extracted
data were prepared to be inputted in Jerboa, a custom-built software developed in the EU-ADR
project[2] which was run locally to standardize the data aggregation process. After providing
formal approval, local data source experts uploaded aggregated analytical datasets to a com-
mon virtual machine.
Using a custom-built analysis tool (a Microsoft Access interface for Stata [StataCorp. 2013.
Stata Statistical Software: Release 13. College Station, TX: StataCorp LP] and LaTeX [https://
www.latex-project.org/]), local experts could test the extracted components in any possible log-
ical combinations by using Boolean operators (i.e. AND, OR, AND NOT). This strategy, we
referred to as “the component algorithm strategy”, allowed local experts to build more complex
case-finding strategies (composite algorithms) by combining two or more of the extracted com-
ponents as a mean of inclusion, exclusion or refinement criteria.The process of testing different
combinations of components was led separately by each local expert, who finally chose a partic-
ular combination of components as the recommended composite algorithm for the identifica-
tion of T2DM in the relevant data source. The local experts, the clinical experts and the central
study leader held a series of conference calls to discuss the final choice about the recommended
composite algorithm, but in case of disagreement the local expert opinion prevailed. A com-
ment describing the reasons behind the choice was recorded together with an estimate, either
objective or subjective, of the expected sensitivity and PPV. This information, as well as the
minutes from the conference calls, was stored and intended as a source of reusable knowledge.
Presentation of results
Results from the application of individual components and recommended composite algo-
rithms were compared across data sources and presented as age-specific percentages of subjects
identified in the study population of the corresponding data source.
In each participating data source, the impact of extracted component was assessed with
respect to the total number of subjects identified using the recommended composite algorithm,
which was considered as the reference case population. For this purpose, we calculated: i) the
percentage of subjects identified by each component in the reference case population and ii)
the prevalence rate ratio (PRR) of subjects identified by the recommended composite algorithm
with and without the use of the tested component as additional inclusion criteria, i.e. PRR =
((N in tested component OR in recommended composite algorithm)/ N in recommended com-
posite algorithm)-1.
Patient records were anonymized and de-identified prior to analysis and only aggregated
data were shared across sites therefore no written informed consent was necessary for this
study. Permission for both re-use of the data analyzed in this study as well as for publication of
the results obtained was granted by each participating organizations’ review board.
The full protocol of the research project is publicly available on the electronic register of
observational studies of the European Network of Centers for Pharmacoepidemiology and
Pharmacovigilance (http://www.encepp.eu/encepp/viewResource.htm?id=11158).
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Results
Since this was a proof-of-concept study, results presented here are not intended as estimates of
disease frequency.
Overall, the EMIF-Platform provided for this study aggregated health data from around 12
million European citizens.
The size of the study populations selected from the participating data sources ranged from
1600 to 3.4 million subjects. Components algorithms included in at least one recommended
composite algorithms are reported in Table 2.
Table 2. Component algorithms description.
Component algorithm
acronym
Algorithm description Record retrieval rules* Case’s
index date
DIAG_T2DM_PC Patients who have1 diagnoses of T2DM
recorded in a primary care setting
Records of (Diabetes type 2) occurs in [diagnosis fields] of
[tables collected during primary care]
1st record
DIAG_T2DM _SC Patients who have1 diagnoses recorded in a
secondary care setting
Records of (Diabetes type 2) occurs in [diagnosis fields] of
[tables collected during secondary care]
1st record
DIAG_T2DM _INP Patients who1 diagnoses recorded during a
hospital admission
Records of (Diabetes type 2) occurs in [diagnosis fields] of
[tables collected during inpatient care]
1st record
DIAG_DMUNSPEC Patients who1 diagnoses of unspecified
diabetes recorded in primary, secondary, or
inpatients care
Records of (Diabetes unspecified) occurs in [diagnosis
fields] of [tables collected in primary, secondary, or
inpatients care]
1st record
DIAG_DMUNSPEC_OTH Patients who have1 diagnoses recorded in a
setting other than primary, secondary, or
inpatients care
Records of (Unspecified diabetes) occurs in [diagnosis
fields] of [tables collected in other settings]
1st record
DIAG_T1DM Patients who have1 diagnoses of T1DM
recorded in any care setting
Records of (Diabetes mellitus type I) occurs in [diagnosis
fields] of [any table collecting diagnoses]
1st record
DIAG_EXCL Patients who have1 diagnoses of conditions
excluding T2DM other than T1DM recorded in
any care setting
Records of ((Metabolic problems around pregnancy) OR
(Metabolic/pancreatic problems, non type 2 diabetes) OR
(Polycystic Ovary Syndrome) occurs in [diagnosis fields]
of [any table collecting diagnoses]
1st record
DRUG_INSULIN_ONE Patients who have1 recorded prescriptions/
dispensings of insulin
Records of (Insulins and analogues) occurs in [ATC field]
of [drugs tables]
1st record
DRUG_INSULIN Patients who have2 recorded prescriptions/
dispensings of insulin in a calendar year
Records of (Insulins and analogues) occurs in [ATC field]
of [drugs tables]
2nd record
DRUG_ORAL_ONE Patients who have1 recorded prescriptions/
dispensings of non-insulin antidiabetic drugs
Records of (Drugs used in diabetes, excl insulin) occurs in
[ATC field] of [drugs tables]
1st record
DRUG_ORAL Patients who2 prescriptions/dispensings of
non-insulin antidiabetics in a calendar year
Records of (Drugs used in diabetes, excl insulin) occurs in
[ATC field] of [drugs tables]
2nd record
TEST_GLUCO5_1YR Patients who have5 records of utilization of
blood glucose measurements within 1 year
Records of (Blood glucose measurement) occurs in [code
of test field] of [tables collecting laboratory test results or
dispensings]
5th record
TEST_GLUCO2_PYEAR_5YRS Patients who have2 records of utilization of
blood glucose measurements per year for 5
consecutive years
Records of (Blood glucose measurement) occurs in [code
of test field] of [tables collecting laboratory test results or
dispensings]
2nd record
LABVAL_ HbA1c Patients who have2 laboratory results
recorded from a glycated hemoglobin test
higher than 6.5% (48 mmol/mol)
Records of (Glycated Haemoglobin) occurs in [code of
test field] of [tables collecting laboratory test results] AND
[result field] of the same record is higher than 6.5% (or 48
mmol/mol, according to unit of measurement adopted in
the table)
2nd record
LABVAL_FAST_GLUC Patients who have2 laboratory results
recorded from a fasting plasma glucose
measurement higher than 126 mg/dl)
Records of (Fast gluc) occurs in [code of test field] of
[tables collecting laboratory test results] AND [result field]
of the same record is higher than 126 mg/dl
2nd record
LABVAL_LCURVE_GLUC Patients who have2 laboratory results
recorded from a glucose tolerance test higher
than 200 mg/dl
Records of (LcurveGLuc) occurs in [code of test field] of
[tables collecting laboratory test results] AND [result field]
of the same record is higher than 200 mg/dl
2nd record
*Codes and free text keywords corresponding to the medical concepts embedded in component algorithms (in brackets) are reported in S1 Table.
doi:10.1371/journal.pone.0160648.t002
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In Fig 2 four examples of comparisons of age band-specific results from individual component
algorithms across data sources are shown. The full list of comparisons concerning all those compo-
nents extracted from at least two data sources and included in at least one recommended composite
algorithm are available as supporting information in S1 Fig. As for DIAG-based components very
different performances were associated to the healthcare setting of data collection (primary, second-
ary, inpatient care). The component DRUG_ORAL (i.e.2 records of non-insulin antidiabetic
drugs utilization in one calendar year) and DRUG_INSULIN (i.e.2 records of insulin utilization
in one calendar year) were extracted in all the participating PCDs and RLDs and resulted in a com-
parable age band-specific percentage of subjects identified in the respective study populations.
The data source tailored recommended composite algorithms are shown in Fig 3 together
with the comments of the local experts. The PCD from UK and the BD from Estonia adopted
the component algorithm based on T2DM diagnoses from primary care (DIAG_T2DM_PC)
only as the recommended choice. The HD from Spain excluded from the pool of subjects iden-
tified through inpatients diagnoses of T2DM (DIAG_T2DM_INP) those with a recorded diag-
nosis of type 1 diabetes (DIAG_T1DM). Only three data sources (the PCD from Italy and the
RLDs from Denmark and Italy) had previous validation studies available [25, 27, 28]. They all
adopted a final composite algorithm based on the relevant validation study.
Fig 2. Comparison of results from individual component algorithms: four examples.
doi:10.1371/journal.pone.0160648.g002
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The Dutch PCD added a sensitive pattern of utilization of non-insulin antidiabetic drugs
(i.e. DRUG_ORAL_ONE) as inclusion criterion, due to the observed low sensitivity of the
DIAG-based algorithm DIAG_T2DM_PC in this data source. The Dutch RLD chose to include
only subjects utilizing non-insulin antidiabetics, because the available DIAG-based component
that used diagnoses from inpatients setting was considered unreliable by local experts.
Through the application of the recommended composite algorithm, the lowest percentage
of study population was identified in the Estonian BD, 3.5%, while the highest in the Spanish
HD, 15.7%. In the RLDs it ranged from 4.1% to 7.5% while in PCDs from 6.8% to 8.6%. The
age band-specific percentages of the total case populations identified using the recommended
composite algorithms showed more comparable results across all participating data sources
(Fig 3). The expected sensitivity of the recommended composite algorithms, as reported by
local experts either from previous validation studies or from subjective judgement, was>0.9 in
all data sources except for the Italian and Dutch RLDs for which a sensitivity between 0.7 and
0.9 was expected. As for PPV, the Italian and Danish RLDs only reported an expected value
ranging from 0.7 and 0.9 while for the remaining data sources the Fig was>0.9.
The union of any extracted DIAG-based component among the five intended as inclusion
criteria identified from 93 to 100% of the reference case population in PCDs (Table 3), 100% in
both BD and HD, and from 15% to 73% in RLDs. In RLDs, DRUG-based components identi-
fied from 81% to 100% of the respective total case population, while from 58% to 83% in PCDs.
TEST-based components were included in the recommended composite algorithm of the Dan-
ish RLD only in which these algorithms identified 44% of the total case population. Although
TEST-based components were also extracted from the Italian RLD, they were not included in
the recommended composite algorithm since they would have almost doubled the total case
population (PRR = +79.2%), thus suggesting a too low specificity. LABVAL-based algorithms
were included in the recommended composite algorithm of the Italian PCD only: overall, the
three components from this data domain identified 46% of the total case population. Notably,
subjects from the same data source could be identified by one or more component thus the per-
centages reported above may overlap.
Discussion
Through the application of the standard data derivation procedure tested in this study, cases of
T2DM were identified in eight distinct sources of health data with heterogeneous characteris-
tics. Logical combinations of standardized component algorithms, each based on a single data
domain, were used to build data source-tailored case-finding algorithms. This “component
algorithm strategy” facilitated both benchmarking and interpretation of results across data
sources. It also allowed the assessment of the impact of individual standardized component
algorithms on the total population of cases retrieved in each participating data source that ulti-
mately provided insight into the strengths and limitations of each data source with respect to
the identification of T2DM cases.
Compared to previous projects that aimed to combine different European sources of EHR
for research purposes,[2, 3] the main innovation of the standard procedure tested in this study
was the use of component algorithms as building blocks that could be combined to create more
complex case-finding algorithms. As demonstrated by the results presented here, in the context
of a multi-national, multi-data source study, the “component algorithm strategy” represents an
extremely flexible approach for generating EHR-driven[6] case-finding algorithms in a stan-
dardized fashion: on the one hand, it allows the local experts’ knowledge of the EHR “natural
system”[8] to be fully leveraged, avoiding loss of information and assuring the correctness of
the derived information, while, on the other hand, it facilitates the interpretation and
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Fig 3. Recommended composite algorithms: age band-specific percentages of subjects identified on the
relevant total study population. PPV: Positive Predictive Value.
doi:10.1371/journal.pone.0160648.g003
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Table 3. Impact of extracted component algorithms on total case population identified in each participating data source through the application of
the relevant recommended composite algorithm.
COMPONENT ALGORITHMS (B)° RECOMMENDED COMPOSITE ALGORITHMS (A)
RLD-I RLD-DK RLD-N PCD-UK PCD-N PCD-I BD HD
N 3391177 1372883 1405220 3278013 992924 945691 22430 15713
N in A 254045 77616 57712 253197 67096 81658 779 2466
% of A in
N
7.5 5.7 4.1 7.7 6.8 8.6 3.5 15.7
DIAG_T2DM_PC (1 diagnosis from primary care) N in B n.e. n.e. n.e. 253197 62191 43438 779 n.e.
% of B in
A
- - - 100.0% 92.7% 52.6% 100.0% -
PRR if B
added
- - - +0.0% +0.0% +0.6% +0.0% -
DIAG_T2DM_INP (1 T2DM diagnosis from inpatient care) N in B 95303 27887 13098 n.e. n.e. n.e. n.e. 2520
% of B in
A
37.5% 35.9% 15.1% - - - - 100.0%
PRR if B
added
+0.0% +0.0% +7.6% - - - - +2.2%
DIAG_T2DM_SC (1 T2DM diagnosis from secondary care) N in B n.e. 35744 n.e. n.e. n.e. n.e. n.e. n.e.
% of B in
A
- 46.1% - - - - - -
PRR if B
added
- +0.0% - - - - - -
DIAG_DMUNSPEC (1 unspecified diabetes diagnosis from
any healthcare setting)
N in B 191999 n.e. n.e. n.e. n.e. 79035 n.e. n.e.
% of B in
A
73.2% - - - - 94.3% - -
PRR if B
added
+2.4% - - - - +2.5% - -
DIAG_ DMUNSPEC_OTH (1 unspecified diabetes
diagnosis from co-payment exemption)
N in B 149806 n.e. n.e. n.e. n.e. n.e. n.e. n.e.
% of B in
A
59.0% - - - - - - -
PRR if B
added
+0.0% - - - - - - -
DIAG_T1DM (1 type 1 diabetes diagnoses from any
healthcare setting)
N in B 18147 17896 n.e. n.e. 8816 2050 164 78
% of B in
A
6.9% 18.1% - - 8.8% 0.0% 2.8% 0.0%
PRR if B
added
+0.2% +4.9% - - +4.3% +2.5% +18.2% +3.2%
DIAG_EXCL (1 diagnoses of other types of diabetes or
glucose intolerance)
N in B 13741 7895 2904 n.e. n.e. 5782 n.e. 78
% of B in
A
1.1% 1.8% 1.5% - - 0.3% - 1.7%
PRR if B
added
+4.3% +8.3% +3.5% - - +6.8% - +1.5%
DIAG_T2DM_PCOR DIAG_T2DM_INPOR
DIAG_T2DM_SCOR DIAG_DMUNSPECOR
DIAG_DMUNSPEC_OTH
N in B 191999 43622 13098 253197 62191 79035 779 2520
% of B in
A
73.2% 56.2% 15.1% 100.0% 92.7% 94.3% 100.0% 100.0%
PRR if B
added
+2.4% +0.0% +7.6% +0.0% +0.0% +2.5% +0.0% +2.2%
DRUG_INSULIN (2 prescriptions/dispensings of insulin in
one calendar year)
N in B 45522 22074 21192 41019 15020 11607 n.e. n.e.
% of B in
A
17.9% 25.4% 25.8% 16.1% 19.0% 12.3% - -
PRR if B
added
+0.0% +3.0% +10.9% +0.1% +3.4% +2.0% - -
(Continued)
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Table 3. (Continued)
DRUG_INSULIN_ONE (1 prescriptions/dispensings of
insulin)
N in B 62341 23319 0 0 17719 0 18 0
% of B in
A
21.2% 26.5% - - 22.0% - 1.5% -
PRR if B
added
+3.4% +3.6% - - +4.4% - +0.8% -
DRUG_ORAL (2 prescriptions/dispensings of NIAD in one
calendar year)
N in B 216338 57153 57712 136370 51589 45624 - 0
% of B in
A
85.2% 71.0% 100.0% 51.7% 76.9% 53.0% - -
PRR if B
added
+0.0% +2.7% +0.0% +2.1% +0.0% +2.9% - -
DRUG_ORAL_ONE (1 prescriptions/dispensings of NIAD) N in B 273952 61604 0 0 54181 62110 45 0
% of B in
A
87.5% 72.7% - - 80.8% 70.6% 5.8% -
PRR if B
added
+20.3% +6.7% - - +0.0% +5.4% +0.0% -
DRUG_INSULINOR DRUG_INSULIN_ONEOR
DRUG_ORALOR DRUG_ORAL_ONE
N in B 295676 70405 64016 151576 58355 65076 40 0
% of B in
A
93.0% 81.1% 100.0% 57.7% 82.6% 73.1% 50.0% -
PRR if B
added
+23.4% +9.6% +10.9% +2.2% +4.4% +6.6% +4.1% -
TEST_TEST_GLUCO5_1YR (5 glycated hemoglobin tests
in 1 year)
N in B 266940 16999 0 0 0 0 0 0
% of B in
A
45.8% 21.6% - - - - - -
PRR if B
added
+59.3% +0.3% - - - - - -
TEST_GLUCO2_PYEAR_5YRS (2 glycated hemoglobin
testsper year during 5 consecutive years)
N in B 172784 28583 0 0 0 0 0 0
% of B in
A
32.6% 36.1% - - - - - -
PRR if B
added
+35.4% +0.7% - - - - - -
TEST_GLUCO5_1YROR TEST_GLUCO2_PYEAR_5YRS N in B 335466 34801 0 0 0 0 0 0
% of B in
A
52.8% 44.1% - - - - - -
PRR if B
added
+79.2% +0.8% - - - - - -
LABVAL_FAST_GLUC (2 fasting glucose values >126mg/
dl)
N in B 0 0 0 0 0 32153 0 0
% of B in
A
- - - - - 38.6% - -
PR if B
added
- - - - - +0.8% - -
LABVAL_HbA1c (2 glycated hemoglobin value >6.5%) N in B 0 0 62400 0 44271 20196 0 0
% of B in
A
- - 65.1% - 63.6% 24.1% - -
PRR if B
added
- - +43.0% - +2.4% +0.7% - -
LABVAL_LCURVE_GLUC (2 glucose tolerance test values
>200mg/dl)
N in B 0 0 0 0 0 32 0 0
% of B in
A
- - - - - 0.0% - -
PRR if B
added
- - - - - +0.0% - -
(Continued)
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benchmarking of results obtained even across data sources with very different characteristics.
Notably, the data derivation procedure tested in this study requires that all component algo-
rithms locally available for the identification of the condition of interest should be extracted,
tested and stored regardless of whether they will be subsequently included in the final recom-
mended composite algorithm. This also gives to investigators and local experts the chance to
tweak the preferred identification algorithm at the study design stage, according to the study
questions.
Gaining insight into cases identified by data source-tailored case-finding
algorithms
In this study, the composite algorithms recommended by local experts for the identification of
T2DM were extremely variable, resulting, however, in a selection of cases that are likely to rep-
resent the best possible local approximation of the true case identification. Indeed, since the
age-specific prevalence of diabetes is expected to be fairly homogeneous across the geographic
areas we are considering,[29] the observed differences in terms of percentage of the corre-
sponding study populations can be interpreted in light of both the specific components
adopted and of relevant data sources’ characteristics. Among all data sources, the highest per-
centage of cases was identified in HD because this data source only captures subjects who visit
the hospital, who, by definition, will have a higher burden of disease with respect to the general
population. On the other extreme, the BD showed the lowest percentage, possibly because peo-
ple volunteering to participate in this data source are slightly healthier than the general popula-
tion. Both HD and BD identify patients with T2DM using DIAG-based component only.
However, while in HD cases were identified among inpatients only who are expected to be at a
more advanced stage of the disease and more likely to have comorbidities,[5] in BD character-
istics of cases were probably more representative of patients with T2DM in the corresponding
source population, because diagnoses are recorded in a primary care setting. As for the three
primary care data sources, the Italian PCD adopted a case finding strategy based on data from
DIAG and LABVAL. This strategy was expected to be very sensitive. Moreover, in a previous
validation study, it was also proven to have the highest possible PPV. [27] Therefore, its recom-
mended algorithm can be considered an excellent approximation of a true case identification
and the observed percentage of cases can be assumed to be a valid estimate of the prevalence of
T2DM in the correspondent source population. In the PCD from UK a lower percentage of
cases was identified compared to the Italian PCD. This result could be due to a slight
Table 3. (Continued)
LABAL_FAST_GLUCOR LABAL_HbA1cOR
LABAL_LCURVE_GLUC
N in B 0 0 62400 0 44271 38764 0 0
% of B in
A
- - 65.1% - 63.6% 46.5 - -
PRR if B
added
- - +43.0% - +2.4% +1.0% - -
Since patients can be identified by more than one component algorithms, percentages may overlap.
Grey cells correspond to component algorithms that were included in the relevant recommended composite algorithm.
NIAD: Non-Insulin Antidiabetic Drugs.
A = recommended composite algorithm.
B = tested component algorithm(s).
N = Study population.
PRR = prevalence rate ratio of “A or B” in N with respect to the percentage of A in N.
n.e. = not extracted
doi:10.1371/journal.pone.0160648.t003
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underreporting of diagnoses in the data source. As for the Dutch PCD, the age-specific percent-
age of detected cases was almost identical to that observed in the PCD from UK. However, in
the Dutch PCD a DRUG-based algorithm was adopted as additional inclusion criterion to the
DIAG-based component DIAG_T2DM_PC, since the latter was not sensitive enough when
used alone. In fact, general practitioners participating to the Dutch PCD often record diagnoses
using free text description which may sometimes remain elusive to the keywords-based
retrieval process. Among RLDs, the percentage of the population identified in the Dutch RLD
was slightly lower than that observed in the other two RLDs from Italy and Denmark respec-
tively. Indeed, local experts of the Dutch RLD recommended the use of one single DRUG-
based component (DRUG_ORAL) as the preferred case-finding algorithm, while the other two
data sources, on the grounds of previous validation studies,[25, 28] adopted more complex
composite algorithms that allowed to increase sensitivity by including also components based
on DIAG and/or TEST. In particular, the Danish RLD was the only data source collecting diag-
noses from secondary care. Notably, TEST-based components, which identify patients through
specific patterns of utilization of glycated haemoglobin tests, were not included in the Italian
RLD since they resulted to be far more unspecific than in the Danish RLD. This was clearly
showed when the impact of TEST-based components on the total population of cases identified
in the two data sources was observed. Such a difference was probably due to local healthcare
system organization and guidelines with respect to diagnosis and follow-up of diabetic
patients.
Understanding quality of a local case-finding algorithm
In studies utilizing routinely collected health data, understanding the quality of local case-find-
ing algorithms is paramount for the interpretation of study findings[11, 30] and a fortiori in
multi-data source studies. The component algorithm strategy proposed in this study can indi-
rectly provide approximation of algorithm validity indexes, even when no formal validation
studies are available for one or more of the participating data sources. This is attained through
the benchmarking of components and composite algorithms across data sources with similar
characteristics but collecting data from different geographic areas or vice versa.
Indeed, in this study, cases in PCDs were basically identified through primary care diagno-
ses and are thus expected to be fairly representative of the T2DM patients in the corresponding
source populations. In RLDs, instead, most of cases were captured through non-insulin antidi-
abetic drugs utilization which cannot identify those patients at a earlier stage of the disease
who are not on drug treatment (do diet only) and may also misclassify T2DM with other dis-
eases for which the same drugs can sometimes be used (e.g. polycystic ovary syndrome).[4]
Supposing that the validity of the latter case-finding algorithm was completely unknown, data
reported in Table 3 can be used to obtain an approximation of its expected sensitivity and PPV.
As an example, the Dutch RLD, which used a case-finding algorithm based on the utilization of
non-insulin antidiabetics only (i.e. DRUG_ORAL) can be considered. Since sensitivity corre-
sponds to the percentage of subjects with a true diagnosis of T2DM who also have the DRU-
G_ORAL pattern of non-insulin antidiabetic drugs utilization, this percentage can be
estimated from the Dutch PCD to be around 77%, or slightly lower if we accept that sensitivity
in the Dutch PCD is not 100% (the corresponding percentage in the other two PCD data
sources is lower than 55%). PPV, instead, is the percentage of subjects utilizing oral antidia-
betics who really have type 2 diabetes. In this case, value higher than 90% is expected since
other indications for such drugs have a very low prevalence.[4] In fact, this is also confirmed in
both PCDs from Italy and UK where the component DRUG_ORAL added less than 3% of
cases when used as additional inclusion criteria.
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Tailoring selection of components to a research question
Since this study was solely intended as an exercise to test the feasibility of the methodology pro-
posed, the research question was rather generic and, consequently, not all the composite algo-
rithms were chosen with the primary objective of addressing specificity or sensitivity. In
general, the preferences of local experts were more often directed towards sensitivity, at
expense of specificity, with the notable exception of RLD-NL. Diagnosis-based components
were selected preferentially because of their face validity. Components based on unspecified
type of diabetes (DIAG_DMUNSPEC or DIAB_OTH) were used in PCD-I and RLD-I due to
specific characteristics of the local data source. Moreover, components that minimally or
slightly increased capture were generally included, while those which were not specific were
dropped if they inflated capture, e.g DRUG_INSULIN and DRUG_ORAL in PCD-UK, in
order to avoid misclassification with type 1 with type 2 diabetes.
Indeed, at the design stage of a specific study, the proposed data derivation procedure allows
investigators and local experts to modify their preferred identification algorithm according to
the type of study question or sensitivity analysis. In the case of a study involving T2DM, if spec-
ificity is important, they may switch to DIAG-based components at the expenses of sensitivity.
This may happen, for instance, when studying occurrence of organ complications in patients
with T2DM. In case sensitivity is important, they may add other inclusion criteria, like TEST-
based components: this may be recommended in safety studies. Finally, if homogeneity across
different data sources is important, investigators and local experts may agree to adopt a
DRUG-based strategy.
Limitations
Although this was a proof-of-concept study in which results obtained were not intended as estimates
of disease frequencies, limitations that might have biased the results and comparisons discussed in
this manuscript must be acknowledged. In particular, formal validation of the retrieved cases against
medical chart review was not performed as well as important variables other than age were not con-
sidered for stratification of results. Finally, identifying T2DMwith an algorithm that is not validated
represents a limitation because the estimates of validity indices rely on the subjective judgment of
the local expert. Nevertheless, in a multi-national, muti-data source study, in absence of a previously
validated algorithm, the local expert recommendation remained the best possible choice.
Conclusions
Through the identification of T2DM cases, this study demonstrates that the standard proce-
dure for data derivation developed within the EMIF project represent a methodological
advancement for the execution of multi-national, multi-data source studies. In fact, on the
basis of a shared definition of any event of interest, the procedure assures interoperability of
heterogeneous EHR systems and allows establishing data-source tailored case-identification
algorithm in a standardized fashion, providing sufficient information for contextualization and
correct interpretation of study results and generating transparent and reusable documentation
on the entire data derivation process. Further studies are warranted to explore the validity of
different components and composite algorithms as well as the heterogeneity of the population
identified across data sources.
Supporting Information
S1 Fig. Comparison of results from individual component algorithms.
(PDF)
Type 2 Diabetes Identification in Heterogeneous Data Sources
PLOS ONE | DOI:10.1371/journal.pone.0160648 August 31, 2016 15 / 18
S1 Table. Mapping of local codes and free text keywords corresponding to the medical con-
cepts embedded in the component algorithms adopted for type 2 diabetes identification.
(DOC)
Author Contributions
Conceptualization: RG GR IL PRMJS.
Data curation: GR RG PR.
Formal analysis: RG GR.
Investigation: RG IL PA RvW DA SR AP LP LT MAM PC PR.
Methodology: RG GR IL PR.
Software: RG PR.
Supervision: RG.
Visualization: GR RG.
Writing – original draft: GR RG IL.
Writing – review & editing: GR IL NS AKL PA PE RvW DA SRM-LT HA AP LP JC LT
MAM RH PC FL MS JvdL MJS PR RG.
References
1. Richesson RL, Horvath MM, Rusincovitch SA. Clinical research informatics and electronic health
record data. Yearb Med Inform 2014; 9(1):215–23.
2. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic
healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.
Pharmacoepidemiol Drug Saf 2011 Jan; 20(1):1–11. doi: 10.1002/pds.2053 PMID: 21182150
3. Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour JC, et al. Harmonization process for the
identification of medical events in eight European healthcare databases: the experience from the EU-
ADR project. J AmMed Inform Assoc 2013 Jan 1; 20(1):184–92. doi: 10.1136/amiajnl-2012-000933
PMID: 22955495
4. Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, et al. A comparison of
phenotype definitions for diabetes mellitus. J AmMed Inform Assoc 2013 Dec; 20(e2):e319–e326. doi:
10.1136/amiajnl-2013-001952 PMID: 24026307
5. Morley KI, Wallace J, Denaxas SC, Hunter RJ, Patel RS, Perel P, et al. Defining disease phenotypes
using national linked electronic health records: a case study of atrial fibrillation. PLoS One 2014; 9(11):
e110900. doi: 10.1371/journal.pone.0110900 PMID: 25369203
6. Pathak J, Kho AN, Denny JC. Electronic health records-driven phenotyping: challenges, recent
advances, and perspectives. J AmMed Inform Assoc 2013 Dec; 20(e2):e206–e211. doi: 10.1136/
amiajnl-2013-002428 PMID: 24302669
7. Overby CL, Pathak J, Gottesman O, Haerian K, Perotte A, Murphy S, et al. A collaborative approach to
developing an electronic health record phenotyping algorithm for drug-induced liver injury. J AmMed
Inform Assoc 2013 Dec; 20(e2):e243–e252. doi: 10.1136/amiajnl-2013-001930 PMID: 23837993
8. Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. J AmMed Inform
Assoc 2013 Jan 1; 20(1):117–21. doi: 10.1136/amiajnl-2012-001145 PMID: 22955496
9. Valkhoff VE, Coloma PM, Masclee GM, Gini R, Innocenti F, Lapi F, et al. Validation study in four health-
care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of
drug-related upper gastrointestinal bleeding risk. J Clin Epidemiol 2014 Aug; 67(8):921–31. doi: 10.
1016/j.jclinepi.2014.02.020 PMID: 24794575
10. Gini R, Schuemie M, Brown J, Ryan P. Data Extraction And Management In Networks Of Observational
Health Care Databases For Scientific Research: A Comparison Among EU-ADR, OMOP, Mini-Sentinel
And MATRICE Strategies. eGEMs 2016; 4(1, Article 2).
Type 2 Diabetes Identification in Heterogeneous Data Sources
PLOS ONE | DOI:10.1371/journal.pone.0160648 August 31, 2016 16 / 18
11. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies
Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med
2015 Oct; 12(10):e1001885. doi: 10.1371/journal.pmed.1001885 PMID: 26440803
12. Conway M, Berg RL, Carrell D, Denny JC, Kho AN, Kullo IJ, et al. Analyzing the heterogeneity and com-
plexity of Electronic Health Record oriented phenotyping algorithms. AMIA Annu Symp Proc 2011;
2011:274–83. PMID: 22195079
13. Trifiro G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, et al. Combining multiple health-
care databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med
2014 Jun; 275(6):551–61. doi: 10.1111/joim.12159 PMID: 24635221
14. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESCGuidelines on diabetes,
pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013
Oct; 34(39):3035–87. doi: 10.1093/eurheartj/eht108 PMID: 23996285
15. Gini R, Francesconi P, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, et al. Chronic disease prevalence
from Italian administrative databases in the VALORE project: a validation through comparison of popu-
lation estimates with general practice databases and national survey. BMC Public Health 2013; 13:15.
doi: 10.1186/1471-2458-13-15 PMID: 23297821
16. Vlug AE, van der LJ, Mosseveld BM, vanWijk MA, van der Linden PD, SturkenboomMC, et al. Post-
marketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999
Dec; 38(4–5):339–44. PMID: 10805025
17. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network
(THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care
2011; 19(4):251–5. PMID: 22828580
18. Nexo BA, Pedersen L, Sorensen HT, Koch-Henriksen N. Treatment of HIV and risk of multiple sclero-
sis. Epidemiology 2013 Mar; 24(2):331–2.
19. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing
data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions.
Clin Epidemiol 2012; 4:303–13. doi: 10.2147/CLEP.S37587 PMID: 23204870
20. Herk-Sukel MP, Lemmens VE, Poll-Franse LV, Herings RM, Coebergh JW. Record linkage for pharma-
coepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf 2012 Jan; 21(1):94–103.
doi: 10.1002/pds.2205 PMID: 21812067
21. Mayer MA, Furlong LI, Torre P, Planas I, Cots F, Izquierdo E, et al. Reuse of EHRs to Support Clinical
Research in a Hospital of Reference. Stud Health Technol Inform 2015; 210:224–6. PMID: 25991136
22. Sancho JJ, Planas I, Domenech D, Martin-Baranera M, Palau J, Sanz F. IMASIS. A multicenter hospital
information system—experience in Barcelona. Stud Health Technol Inform 1998; 56:35–42. PMID:
10351871
23. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, et al. Cohort Profile: Estonian Bio-
bank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2015 Aug; 44(4):1137–47.
doi: 10.1093/ije/dyt268 PMID: 24518929
24. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its compli-
cations. Part 1: Diagnosis and classification of diabetes mellitus. Geneva; 1999. Report No.: WHO/
NCD/NCS/99.2.
25. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register:
trends in incidence, prevalence and mortality. Diabetologia 2008 Dec; 51(12):2187–96. doi: 10.1007/
s00125-008-1156-z PMID: 18815769
26. Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, ThompsonWK, Armstrong LL, et al. Use of
diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-
wide association study. J AmMed Inform Assoc 2012 Mar; 19(2):212–8. doi: 10.1136/amiajnl-2011-
000439 PMID: 22101970
27. Gini R, Schuemie MJ, Mazzaglia G, Lapi F, Pasqua A, Dazzi P, et al. Automatic identification of stages
of type 2 diabetes, hypertension, ischaemic heart disease and heart failure from Italian General Prac-
tioners' electronic medical records: a validation study [Abstract]. Pharmacoepidemiol Drug Saf Sep
2015; 24:1–587 2015.
28. Gini R, Schuemie MJ, Mazzaglia G, Lapi F, Francesconi P, Pasqua A, et al. Identifying chronic condi-
tions from data sources with incomplete diagnostic information: the case of Italian administrative data-
bases [Abstract]. Pharmacoepidemiol Drug Saf Sep 2015; 24:1–587 2015.
29. Prevalence estimates of diabetes, adults aged 20–79 years, 2011. OECD-iLibrary 2011Available from:
URL: http://www.oecd-ilibrary.org/sites/9789264183896-en/01/14/g1-14-01.html?itemId=/content/
chapter/9789264183896-17-en&_csp_=bd0a209a2ba2bc37c7e28851b7808bdc
Type 2 Diabetes Identification in Heterogeneous Data Sources
PLOS ONE | DOI:10.1371/journal.pone.0160648 August 31, 2016 17 / 18
30. Hernan MA. With great data comes great responsibility: publishing comparative effectiveness research
in epidemiology. Epidemiology 2011 May; 22(3):290–1. doi: 10.1097/EDE.0b013e3182114039 PMID:
21464646
Type 2 Diabetes Identification in Heterogeneous Data Sources
PLOS ONE | DOI:10.1371/journal.pone.0160648 August 31, 2016 18 / 18
